Pneumocystis pneumonia (PCP) is a common opportunistic infection in immunocompromised patients. In general, clinical response to therapy with cotrimoxazole is excellent. However, therapy may be limited by side effects or treatment failure. We present a case of PCP in a 35-year-old male patient with history of heart transplantation and renal failure who was admitted with a 10-day history of fever, nonproductive cough and elevated level of creatinine with a diagnosis of PCP confirmed by chest radiography and in bronchoalveolar lavage specimens. He was treated with trimethoprim-sulphamethoxazole (SMZ/TMP) and primaquine but treatment was completed with reduced dosage of cotrimoxazole, primaquine and with the addition of caspofungin.
INTRODUCTION
The first-line treatment for PCP infection is cotrimoxazole with various adverse effects, including leukopenia, rash, interstitial nephritis and thrombocytopenia (6). So we cannot prescribe it for patients with renal failure and creatinine level rising.
Caspofungin is a beta-1, 3-glucan synthesis inhibitor (antifungal) which in experimental animals has shown activity against PCP (7), but the clinical trials about this matter are rare (8) (9) (10) (11) (12) . We here report our clinical experience with caspofungin in salvage treatment of PCP in a young man with a history of heart trantplantation and Three weeks after completion of treatment, the patient was without any symptoms or signs. We continued cotrimoxazole at a dosage of 800/160 mg as a secondary prophylaxis.
DISCUSSION
Pneumocystis pneumonia (PCP) is a leading cause of morbidity in immunocompromised individuals.
The diagnosis of PCP may be difficult without invasive diagnostic approaches including BAL or biopsy, notably in the non-AIDS immunocompromised host (13) . In patients intolerant of cotrimoxazole, clindamycin plus primaquine, and atovaquone are second-line drugs and pentamidine intravenously is used in more severe form of disease (14) .
Recent studies revealed that PCP is a fungal species with glucan-rich cyst wall (15) . The effect of caspofungin against PCP has been shown in animal models (7), but there is limited clinical experience with this agent. This case may suggest that caspofungin in addition to reduced dose cotrimoxazole may provide advantages in patients intolerant of cotrimoxazole due to renal dysfunction (10, 11) Lobo and colleagues16 in their study reported that the administration of low doses of cotrimoxazole in combination with caspofungin provide an improved treatment protocol for PCP infection, in mice. Other studies also derived benefit from cotrimoxazole in combination with caspofungin in their patient (9, 17) Thus, caspofungin is recommended as a salvage treatment in patients with PCP (18).
Tu et al. (19) reported that the use of cotrimoxazole is associated with various side effects that may not be tolerated by critically ill patients so administration of caspofungin is recommended for PJP after solid organ transplantation. They showed that a combination of caspofungin and low-dose cotrimoxazole was useful in three cases of severe PCP in renal transplant recipients. In the current patient, combination therapy appears to be useful in the face of renal intolerance of full-dose cotrimoxazole.
